SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 22, 2006
CardioVascular BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-51172 | | 33-0795984 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
1635 Village Center Circle, Suite 250
Las Vegas, Nevada
(Address of Principal Executive Offices)
89134
(Zip Code)
Registrant’s telephone number, including area code: 702-839-7200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
CardioVascular BioTherapeutics, Inc. (the “Corporation”) held its Annual Meeting of Stockholders on May 22, 2006. A Definitive Notice and Proxy Statement was filed with the Securities and Exchange Commission on April 14, 2006 and sent to all stockholders of record as of March 31, 2006. There were two proposals on the ballot that were passed by the stockholders: 1) Re-election of the members of the Corporation’s Board of Directors; and 2) Ratification of the appointment of Singer Lewak Greenbaum & Goldstein LLP as the independent registered public accounting firm of the Corporation for the fiscal year ending December 31, 2006.
The results were as follows:
There were present in person or by proxy at said meeting 114,281,801 stockholder shares having voting rights, representing 92.17% of the total number of shares with voting rights outstanding and entitled to be voted at the meeting, representing a quorum.
1) Election of Directors:
| | | | | | | | |
Directors | | | | For | | Against | | Abstain |
Daniel C. Montano | | 114,256,366 | | 0 | | 25,435 |
John W. Jacobs | | 114,263,866 | | 0 | | 17,935 |
Mickael A. Flaa | | 114,263,866 | | 0 | | 17,935 |
Thomas Stegmann | | 114,262,866 | | 0 | | 18,935 |
Wolfgang Priemer | | 114,262,566 | | 0 | | 19,235 |
Alexander G. Montano | | 114,243,041 | | 0 | | 38,760 |
Thomas L. Ingram | | 114,267,891 | | 0 | | 13,910 |
Robert Levin | | 114,267,591 | | 0 | | 14,210 |
Gary Abromovitz | | 114,266,891 | | 0 | | 14,910 |
Joong Ki Baik | | 114,262,916 | | 0 | | 18,885 |
Grant Gordon | | 114,263,391 | | 0 | | 18,410 |
2) Ratification of Appointment of Singer Lewak Greenbaum & Goldstein LLP:
| | | | | | | | |
| | | | | For | | Against | | Abstain |
| | 114,261,846 | | 14,800 | | 5,155 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | CARDIOVASCULAR BIOTHERAPEUTICS, INC. |
| | | |
Date: June 6, 2006 | | | | By: | | /s/ Michael A. Flaa |
| | | | | | | | Michael A. Flaa Chief Financial Officer |
